louisakewell, Author at European Medical Journal - Page 45 of 153

Pfizer Selects Turner & Townsend for Expansion of Its Clinical Research Unit in Belgium

Turner & Townsend, the global professional services consultancy, has successfully delivered the first of two fit outs on behalf of Pfizer Clinical…

New Results from Second Phase 3 Study Show Significant Efficacy of Guselkumab and Superiority Versus Humira® in Treatment of Moderate to Severe Plaque Psoriasis

Orlando, Florida, 3 March, 2017 ― Janssen Research & Development, LLC (Janssen) announced today new findings from two pivotal Phase 3 studies reporting…

Clinical and Preclinical Data on Monalizumab to Be Presented at AACR Annual Meeting 2017

Marseille, France, March 2, 2017 – Innate Pharma SA (the “Company” – Euronext Paris: FR0010331421 – IPH) today announces that data on monalizumab will be…

Introducing the European Medical Journal 2.1

United Kingdom, March 2, 2017: A warm welcome to the year’s first issue of the flagship eJournal, the European Medical Journal. Contained within is a…

Positive Results for Relvar® Ellipta® Lung Function Study in Patients with Well-Controlled Asthma

GlaxoSmithKline plc and Innoviva, Inc. today announced positive headline results from a non-inferiority lung function study

Philips Reinforces Leadership in Image-Guided Therapy Solutions with Global Launch of next Generation Azurion Platform

Amsterdam, the Netherlands, February 22, 2017 – Royal Philips (NYSE: PHG, AEX: PHIA), a leader in health technology, today announced the global launch of…

Janssen Presents Newly-Published Data on the Use of ZYTIGA® (Abiraterone Acetate) Plus Prednisone in the Real-World, Outside the Clinical Trial Setting

Beerse, Belgium, February 17, 2017 – Janssen-Cilag International NV today announced the publication of data revealing radiographic progression-free…

New Data Shows Stelara® (Ustekinumab) Maintained Clinical Response and Remission After Two Years of Treatment in Patients with Moderate to Severe Crohn’s Disease

Barcelona, Spain, February 17, 2017 – Janssen-Cilag International NV (“Janssen”) announced today new two-year data from the ongoing IM-UNITI long-term…

Polyganics’ “STOP NEUROMA” Study Interim Data Shows Reduction in Pain

Groningen, The Netherlands, February 16, 2017 – Polyganics, a privately held medical technology company, announced today that interim results show a…

BIAL and Neurocrine Announce Exclusive North American Licensing Agreement for Opicapone

Porto, Portugal and San Diego, California, February 10, 2017 – BIAL and Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that they have…